Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) in Meningococcal Vaccine-Naïve Participants across a Broad Age Range (2–55 Years) in Japan: a Phase III Randomized Study
-
- Matsuoka Osamu
- Medical Corporation Heishinkai ToCROM Clinic, Japan
-
- Ujiie Mugen
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
-
- Kikuchi Hitoshi
- Meitetsu Hospital, Japan
-
- Otake Sachiko
- Medical Corporation Heishinkai ToCROM Clinic, Japan
-
- Chansinghakul Danaya
- Global Clinical Development Strategy, Sanofi, Thailand
-
- Inoue Takahiro
- Clinical Sciences & Operations, R & D, Sanofi K. K., Japan
-
- Varghese Kucku
- Global Clinical Immunology, Sanofi, USA
-
- Sirisuphmitr Nuchra
- Clinical Study Management, Sanofi, Thailand
-
- Hashiguchi Tomoyuki
- NV Portfolio Strategy & Execution, Sanofi, Japan
-
- Zambrano Betzana
- Global Clinical Development Strategy, Sanofi, Uruguay
-
- Nakama Takahiro
- Global Clinical Development Strategy, Sanofi, Japan
-
- Frago Carina
- Global Clinical Development Strategy, Sanofi, Singapore
-
- Jordanov Emilia
- Global Clinical Development Strategy, Sanofi, USA
-
- Dhingra Mandeep Singh
- Global Clinical Development Strategy, Sanofi, USA
抄録
<p>MenACYW-TT is a quadrivalent meningococcal tetanus toxoid-conjugate vaccine designed to prevent invasive meningococcal disease. The primary objective of this study was to demonstrate non-inferiority of the vaccine seroresponse to a single dose of MenACYW-TT compared with MCV4-DT, a licensed meningococcal quadrivalent diphtheria-conjugate vaccine. This Phase III double-blind, multicenter trial was conducted in meningococcal vaccine-naïve individuals aged 2–55 years in Japan (NCT04368429; jRCT2080225192). Participants were randomized 1:1 to receive either MenACYW-TT (n = 180) or MCV4-DT (n = 180). Functional antibodies against meningococcal serogroups A, C, W, and Y were measured using a serum bactericidal antibody assay with human complement (hSBA) at baseline (D0) and 30 days after vaccination (D30). Seroresponse was defined as a post-vaccination titer ≥1:16 in participants with a baseline titer <1:8; or a ≥4-fold increase in titer in participants with a baseline titer ≥1:8. Safety data were collected for 30 days. Non-inferiority of the seroresponse to MenACYW-TT vs. MCV4-DT was demonstrated on D30 for each serogroup tested (A: 85.6% vs. 65.4%; C: 96.6% vs. 62.6%; W: 87.4% vs. 49.2%; Y: 97.7% vs. 63.5%). MenACYW-TT was well tolerated with no safety concerns identified. A single dose of MenACYW-TT was well tolerated, with a non-inferior seroresponse compared with MCV4-DT. MenACYW-TT could thus be used as an alternative vaccine in meningococcal vaccine-naïve individuals.</p>
収録刊行物
-
- Japanese Journal of Infectious Diseases
-
Japanese Journal of Infectious Diseases 76 (3), 174-182, 2023-05-31
国立感染症研究所